Karyopharm Announces Results from Interim Analysis of Phase 2 SOPRA Study Evaluating Selinexor in Relapsed/Refractory Acute ...
Study Will Not Reach Statistically Significant Improvement in Primary Endpoint of Overall Survival in Patients who are Unfit for Chemotherapy and/or Transplantation; Patients Deriving Benefit to Remain on Study Clinical Development Continuing in Promising …